Patrick Campbell

Matthew Cavender, MD, MPH, discusses a study he led at ESC Congress examining utility of the SCORE2-Diabetes risk score using clinical trial data.

Kausik Ray, MD, MPhil, discusses the results of the INTERASPIRE study and how it improves our understanding of the effects of elevated Lp(a).

ESC 2024: Phase 3 PALISADE trial shows plozasiran significantly lowers triglycerides and pancreatitis risk in FCS; NDA planned by year-end.

Siddharth Patel, MD, MPH, discusses how an AZALEA-TIMI 71 analysis presented at ESC Congress 2024.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.

Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

New study finds ASCVD risk score often misses at-risk patients for first acute coronary syndrome, highlighting need for better prediction methods.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.